Evidence for continuous glucose monitoring: sufficient for reimbursement?

Evidence for continuous glucose monitoring is mounting. Meta‐analyses consistently show lowering of HbA1c, and the first trial reporting a reduction in severe hypoglycaemic events in patients with hypoglycaemia unawareness has recently been presented. The more recent trials studied larger numbers of...

Full description

Saved in:
Bibliographic Details
Published in:Diabetic medicine 2014-02, Vol.31 (2), p.122-125
Main Authors: Heinemann, L., DeVries, J. H.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Blood Glucose Self-Monitoring - economics
Blood Glucose Self-Monitoring - methods
Cost-Benefit Analysis
Diabetes
Diabetes Mellitus - blood
Diabetes Mellitus - drug therapy
Diabetes Mellitus - economics
Endocrinopathies
Evidence-Based Practice
Feeding. Feeding behavior
Fundamental and applied biological sciences. Psychology
Glucose
Humans
Insulin - administration & dosage
Insulin - economics
Insulin Infusion Systems - economics
Insurance, Health, Reimbursement
Medical sciences
Vertebrates: anatomy and physiology, studies on body, several organs or systems
Vertebrates: endocrinology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Evidence for continuous glucose monitoring is mounting. Meta‐analyses consistently show lowering of HbA1c, and the first trial reporting a reduction in severe hypoglycaemic events in patients with hypoglycaemia unawareness has recently been presented. The more recent trials studied larger numbers of patients and may have shown better results because of improved technology. The various combinations of pump and sensor, with automated bolus calculators and low glucose suspend features, make evaluation more challenging from a reimbursement point of view, but evidence seems convincing enough to justify reimbursement for selected patient groups, including those who have shown a substantial improvement in HbA1c during a trial period, and those with hypoglycaemia unawareness who encountered severe hypoglycaemia in the recent past. More data on cost–efficacy are needed.
ISSN:0742-3071
1464-5491
DOI:10.1111/dme.12341